Recombinant IAV H1N1 (A/New Caledonia/20/1999) Hemagglutinin [TBD]

Name: Recombinant IAV H1N1 (A/New Caledonia/20/1999) Hemagglutinin [TBD]
SKU: DAG1604
Rating: 5 (1 reviews)

Recombinant IAV H1N1 (A/New Caledonia 20/1999) Hemagglutinin from Insect Cells [TBD]

COA

SDS

Datasheet

Summary

Product Overview

Recombinant Full-Length H1N1 New Caledonia/20/99 is glycosylated with N-linked sugars, produced using baculovirus vectors in insect cells and its Mw is approximately 72 kDa.The insect cells infected with A9440.1a recombinant baculovirus expressing recombi

Nature

Recombinant

Tag/Conjugate

His

Molecular Weight

72 kDa

Alternative Names

Influenzavirus A; Influenza A virus; Influenza A virus H1N1; H1N1; IAV H1N1; IAV H1N1 Hemagglutinin; IAV H1N1 HA; H1N1 HA

Purity

Greater than 90.0% as determined by: Analysis by SDS-PAGE, HA1 and HA2 bands are observed using SDS-PAGE under reducing conditions.

Format

Liquid or Lyophilized powder

Buffer

25 mM MES, 150mM NaCl, 5% trehalose, 0.1% chaps, pH 5.5

Preservative

None

Storage

Store at -20°C

Introduction

Hemagglutinin (HA) or Haemagglutinin (BE) is an antigenic glycoprotein found on the surface of the influenza viruses. It is responsible for binding the virus to the cell that is being infected. The name "Hemagglutinin" comes from the protein's ability to cause red blood cells (erythrocytes) to clump together ("agglutinate") in vitro. The process is like this: Hemagglutinin (HA) binds to the monosaccharide sialic acid which is present on the surface of its target host cells. The cell membrane then engulfs the virus through endocytosis and forms endosome. The cell then attempts to begin digesting the contents of the endosome by acidifying its interior and transforming it into a lysosome. When the pH within the endosome drops to 6.0, the HA molecule becomes partially unfold, and releasing a very hydrophobic portion of its peptide chain that was previously hidden within the protein. This so-called "fusion peptide" acts like a molecular grappling hook by inserting itself into the endosomal membrane and locking on. Then, when the rest of the HA molecule refolds into a new structure and pulls the endosomal membrane right up next to the virus particle's own membrane, causing the two to fuse together. Once this has happened, the viral RNA genome enters into the cell's cytoplasm.

Keywords

Influenzavirus A; Influenza A virus; Influenza A virus H1N1; H1N1; IAV H1N1; IAV H1N1 Hemagglutinin; IAV H1N1 HA; H1N1 HA

Citations

Have you cited DAG1604 in a publication? Let us know and earn a reward for your research.

Development of rapid diagnostic tests for multiplexed detection of COVID-19 and Influenza diseases

Zülal Bilici, Göknur Gizem Dinç, İlkay Göksu Polat, Esin Akçael, Tamer Yağcı.

Turkish Journal of Biochemistry2025 Sep 1Read Article

Applications: LFA

Reactive species: IAV

"Abstract: Objectives This study investigates diagnosis of upper respiratory diseases with similar clinical symptoms, specifically COVID-19, originated from the SARS-CoV-2 virus, and Influenza infections associated with Influenza viruses. Effective treatment relies on rapid and accurate diagnosis, especially due to pandemic potential. This research aims to develop a multiplex lateral flow assay (LFA) based diagnosis method for detecting SARS-CoV-2 and Influenza A H1N1 viruses simultaneously. Methods Lateral flow assay utilizing gold nanoparticles were developed with specific monoclonal antibodies targeting the nucleocapsid (NP) protein of SARS-CoV-2 and the hemagglutinin (HA) protein of Influenza A H1N1. Multiplexing was achieved by immobilizing two different capture antibodies for both targets on the same test. Recombinant antigens were employed to perform analytical assessments of specificity and cross-reactivity. Results The limit of detection (LOD) of the developed system in both single and multiplex formats was found to be: 1 ng/mL for SARS-CoV-2 NP, 1 × 103 PFU/mL for active viruses and 5 ng/mL for Influenza A H1N1 HA. Negative control experiments confirmed no cross-reactivity among target antigens, demonstrating high assay specificity. The low LOD values and absence of cross-reactivity indicate excellent analytical sensitivity and specificity. Simultaneous detection of both pathogens offers significant advantages for rapid clinical decision-making and infection control. Conclusions Our research presents a potential diagnostic approach utilizing a singular LFA platform for the early and accurate detection of COVID-19 and Influenza infections. The proposed multiplex strategy could improve public health outcomes by facilitating rapid therapeutic intervention and successful disease management during respiratory infection epidemics."

Article snippet: Influenza A H1N1 HA Antigen: IAV H1N1Hemagglutinin protein (DAG1604 IAV H1N1), Influenza A H1N1 HA Antibody1: Magic™ Anti-IAV type A Hemagglutinin H1 Monoclonal antibody, Clone C328 N (Cat. DCAB-TJ049 and Influenza A H1N1 HA Antibody-2: Magic™ Anti-IAV type A Hemagglutinin H1 Monoclonal antibody, Clone C329 N (Cat. DCAB-TJ050) were purchased from Creative Diagnostics.